| Ticker Details |
Denali Therapeutics Inc.
Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
|
| IPO Date: |
December 8, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.98B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.83 | 3.04%
|
| Avg Daily Range (30 D): |
$0.55 | 2.24%
|
| Avg Daily Range (90 D): |
$0.52 | 2.39%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.66M |
| Avg Daily Volume (30 D): |
1.25M |
| Avg Daily Volume (90 D): |
1.38M |
| Trade Size |
| Avg Trade Size (Sh.): |
68 |
| Avg Trade Size (Sh.) (30 D): |
60 |
| Avg Trade Size (Sh.) (90 D): |
60 |
| Institutional Trades |
| Total Institutional Trades: |
3,822 |
| Avg Institutional Trade: |
$2.77M |
| Avg Institutional Trade (30 D): |
$3.11M |
| Avg Institutional Trade (90 D): |
$3.01M |
| Avg Institutional Trade Volume: |
.11M |
| Avg Institutional Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.96M |
| Avg Closing Trade (30 D): |
$6.15M |
| Avg Closing Trade (90 D): |
$6.35M |
| Avg Closing Volume: |
153.45K |
|
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
$-2.84
|
$-.68
|
$-.69
|
|
Diluted EPS
|
$-2.84
|
$-.68
|
$-.69
|
|
Revenue
|
$3.6M
|
$3.6M
|
$M
|
|
Gross Profit
|
|
$3.51M
|
$M
|
|
Net Income / Loss
|
$-511.45M
|
$-127.55M
|
$-128.45M
|
|
Operating Income / Loss
|
$-542.7M
|
$-130.54M
|
$-137.36M
|
|
Cost of Revenue
|
|
$.09M
|
$M
|
|
Net Cash Flow
|
$60.32M
|
$-186.1M
|
$182.3M
|
|
PE Ratio
|
|
|
|
|
|
|
